文献速递慢性肾脏病

缓释烟酸对CKD患者矿物质代谢标志物的影响

The Effect of Extended Release Niacin on Markers of Mineral Metabolism in CKD.
PubMed 文献 · Clin J Am Soc Nephrol · 2017-12-05

本研究基于AIM-HIGH随机双盲安慰剂对照试验,分析352例eGFR<60 ml/min/1.73 m²的CKD患者,比较缓释烟酸(1500或2000 mg)与安慰剂对矿物质代谢标志物的3年影响。结果显示烟酸组血磷每年多降低0.08 mg/dl,3年后平均血磷低0.25 mg/dl,但iFGF23、PTH、钙和维生素D代谢物无显著变化。

要点

  • 缓释烟酸可小幅降低CKD患者血磷水平
  • 烟酸对iFGF23、PTH、钙及维生素D代谢物无显著影响
  • 该研究为烟酸在CKD中降磷作用提供长期证据

核心结论

  • 在CKD患者中,使用缓释烟酸3年可降低血清磷浓度,但不影响其他矿物质代谢标志物。

研究设计与样本

  • 基于AIM-HIGH随机双盲安慰剂对照试验的事后分析,纳入352例eGFR<60 ml/min/1.73 m²且有心脑血管疾病的患者,随机接受缓释烟酸(1500或2000 mg)或安慰剂,随访3年。

主要发现

  • 与安慰剂相比,烟酸组血浆磷酸盐浓度每年多降低0.08 mg/dl(P<0.01)。
  • 3年后烟酸组平均血磷为3.32 mg/dl,安慰剂组为3.57 mg/dl,差异0.25 mg/dl(P=0.03)。
  • 烟酸对血浆iFGF23、PTH、钙和维生素D代谢物无统计学显著影响。

临床怎么用

  • 对于合并心血管疾病的CKD患者,缓释烟酸可能作为辅助降低血磷的选择,但需注意其对其他矿物质代谢指标无显著改善。

局限性

  • 本研究为AIM-HIGH试验的事后分析,样本量有限(352例),结果需在更广泛CKD人群中验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Niacin downregulates intestinal sodium-dependent phosphate transporter 2b expression and reduces intestinal phosphate transport. Short-term studies have suggested that niacin lowers serum phosphate concentrations in patients with CKD and ESRD. However, the long-term effects of niacin on serum phosphate and other mineral markers are unknown. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: The Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides: Impact on Global Health Trial was a randomized, double-blind, placebo-controlled trial testing extended release niacin in persons with prevalent cardiovascular disease. We examined the effect of randomized treatment with niacin (1500 or 2000 mg) or placebo on temporal changes in markers of mineral metabolism in 352 participants with eGFR<60 ml/min per 1.73 m2 over 3 years. Changes in each marker were compared over time between the niacin and placebo arms using linear mixed effects models. RESULTS: Randomization to niacin led to 0.08 mg/dl lower plasma phosphate concentrations per year of treatment compared with placebo (P<0.01) and 0.25 mg/dl lower mean phosphate 3 years after baseline (3.32 versus 3.57 mg/dl; P=0.03). In contrast, randomization to niacin was not associated with statistically significant changes in plasma intact fibroblast growth factor 23, parathyroid hormone, calcium, or vitamin D metabolites over 3 years. CONCLUSIONS: The use of niacin over 3 years lowered serum phosphorous concentrations but did not affect other markers of mineral metabolism in participants with CKD.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Malhotra R, Katz R, Hoofnagle A, et al. The Effect of Extended Release Niacin on Markers of Mineral Metabolism in CKD. Clin J Am Soc Nephrol. 2017. PMID: 29208626. doi:10.2215/CJN.05440517

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。